Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933467 | 0.82 | TSHR (0.38) | CPA1 | |
| SCHEMBL585119 | 0.79 | ANPEP (0.48) | ANPEPENPEPMAPTSLC22A6TDP1 | |
| SCHEMBL23928904 | 0.79 | ITGB3 (0.39) | ITGB3ITGA2BCPA1GRIK1GRIK2 | |
| SCHEMBL1853265 | 0.79 | ITGB3 (0.36) | ITGB3ITGA2BCPA1GRIK1GRIK2 | |
| SCHEMBL20565058 | 0.77 | — | — | |
| SCHEMBL11897680 | 0.76 | ITGB3 (0.35) | ITGB3ITGA2BCPA1 | |
| Acrylamide SCHEMBL21195072 | 0.75 | TSHR (0.46) | ITGB3ITGA2BANPEPENPEPCPA1 | |
| SCHEMBL4075575 | 0.75 | ITGB3 (0.39) | ITGB3ITGA2BCPA1GRIK1GRIK2 | |
| SCHEMBL13168637 | 0.74 | TDP1 (0.41) | ANPEPENPEPMAPTTDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21195073 | 0.74 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2311786-A2 | Methods for synthesis of encoded libraries | Praecis Pharmaceuticals Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | ITGB3 4259/4885ITGA2B 4355/4885ANPEP 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.